Navigation Links
FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer
Date:12/1/2010

WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug Administration advisory committee on Wednesday voted against approving two drugs for the prevention of prostate cancer, the third-highest cancer killer of men.

The panel voted 17-0, with one abstention, that the risks of Merck's Proscar outweighed its benefits, according to the Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.

"In a setting like this, the onus is on the drug to be completely safe, and to show benefit, and I don't think it reached that level," said panel Chairman Dr. Wyndham Wilson, of the National Cancer Institute.

The FDA does not have to heed the advice of its advisory panels, but it typically does.

Research presented to the panel by Merck and GlaxoSmithKline showed a 25 percent decrease in the incidence of low-grade prostate tumors among users of the drugs.

But concern that a small number of men taking the drugs actually developed more aggressive tumors led the panelists to find that the risk of aggressive tumors outweighed the benefit of reducing tumors that are seldom fatal, the wire service reported.

FDA regulators already had several concerns about using the medications for the prevention of prostate cancer, the AP reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated.

Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP.

The panel of outside experts assembled by the FDA is also likely to discuss the overall value of preventing low-grade tumors. According to the FDA, more than three-quarters of the tumors the drugs prevent are slow-growing, meaning they are non-aggressive and probably not life-threatening for anyone with a life expectancy of less than 20 years.

But even if the tumors aren't aggressive, Glaxo has said they often involve unnecessary treatment and biopsies, or surgical procedures, to diagnose cancer, that pose risks of their own.

Also, slightly more aggressive tumors were seen in men taking Avodart and Proscar, compared with those taking placebo pills, according to the FDA. But the pharamaceutical companies say the drugs simply make those tumors easier to detect because they shrink the prostate.

The U.S. National Cancer Institute estimates that 217,730 men will be diagnosed with prostate cancer this year and 32,050 men will die of it.

More information

For more on prostate cancer, visit the U.S. National Library of Medicine.

-- Margaret Steele

SOURCES: U.S. Food and Drug Administration; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
2. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
3. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
4. Teens Should Get Meningitis Booster Shot: CDC Panel
5. Expert Panel Links Popular Bone Drugs to Rare Fracture
6. FDA Panel to Mull Ban on Diet Drug Meridia
7. Experts Support FDA Panels Backing of New Blood Thinner
8. Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
9. FDA Panel Seems Skeptical Over Key Avandia Data
10. FDA Panel Appears Skeptical Over Key Avandia Data
11. NJIT professor heads panel studying sudden car acceleration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 22, 2017 , ... The old adage “you are what ... eating healthy foods. But this well-known piece of nutrition advice ignores that an ... carbohydrates—depends not only on properties of the food but also on properties of ...
(Date:8/22/2017)... ... ... six years, Lightning Labels has sent out a call for users of its custom label ... of their designs. Submissions this year were open from May 18 to July 1 and ... of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... 22, 2017 , ... Five Star Glass is new to the Texas market, but is proudly ... glass for most makes and models, in Grand Prairie, TX, located in the center of ... been a family owned business for the past 40 years with 32 convenient locations in ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without ... abuse and neglect, and the struggles faced while hoping for a better life. ... published author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins ... Managing Member for t4 Leadership Development & Consulting. He has spent his career ... “success”: physician leadership development, servant leadership, data driven process improvement, and supportive technology. ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... LAKEWOOD, Colo. , Aug. 10, 2017  Physical Rehabilitation ... Therapy, located in Lakewood, Colorado . The ... Jeff Lipkin , PT, DPT with his staff of ... the University of Pittsburgh and brings over 10 years of ... Belmar PT marks the 10th PRN clinic ...
(Date:8/8/2017)...   Second-quarter 2017 ... loss per share from continuing operations ... 16 percent to $110 million ... to $161 million Second-quarter ... operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Ind. , Aug. 7, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the third quarter of 2017. ... be paid on or about October 27, 2017 to stockholders ... 22, 2017.  Future declarations of dividends are subject to approval ...
Breaking Medicine Technology: